Bolt Biotherapeutics, Inc. (BOLT) · Oct 23, 2026 · Acquisition

Bolt Biotherapeutics acquisition adds Prana, but dilution reshapes control

Prana acquisition — 13,995.311 Series D shares plus warrants; related financing totals $120 million

Bolt Biotherapeutics’ acquisition and financing broaden the pipeline and extend funding, but new investors and Prana holders will dominate the post-deal ownership.

Bolt is a cash-constrained clinical-stage oncology biotech centered on the BDC-4182 Phase 1/2 program, with $18.1 million in cash and marketable securities at June 30, 2026 and management warning that its resources raised substantial doubt about continuing as a going concern. This filing supplies a much larger strategic reset than a routine registration notice. It documents the legal machinery for acquiring Prana Therapies while issuing up to 13,995.311 shares of Series D non-voting convertible preferred stock and accompanying warrants. 〔0〕 〔1〕

The transaction addresses Bolt’s funding problem, but the financing is not a free extension of the old story. The related announcement describes a $120 million private placement, with up to another $60 million available through warrants, giving Bolt materially more runway than its pre-filing balance sheet. The preferred stock is convertible into common equity subject to stockholder approval and ownership limits, while the registration agreement gives investors a path to resell the converted shares. 〔2〕

The buried cost is a change in who owns and controls the company. The financing and merger announcement indicates that legacy Bolt holders would retain only about 6.9% of the post-transaction common equity on a fully diluted basis, versus roughly 51.7% for former Prana holders and 41.4% for the new financing investors. That makes this closer to a recapitalization and corporate reset than a simple bolt-on acquisition: Bolt gets capital and a new asset base, but existing holders give up most of the economic ownership.

The registration rights themselves are investor protection, not new operating progress. Bolt must file an initial resale registration statement within 75 days of closing and generally faces liquidated damages of 1.0% of an investor’s purchase price per 30-day delay, capped at 5.0%. 〔3〕 This increases the investors’ ability to exit, while leaving the business case dependent on the Prana combination and Bolt’s upcoming BDC-4182 clinical readout.

Bottom line: The deal meaningfully improves Bolt’s financing position and broadens the platform, but it does so by transferring most post-deal ownership to Prana holders and new investors. This is a company reset with real strategic upside and very heavy dilution, not merely a capital raise.

What to watch next

Shareholder approval, merger closing, and BDC-4182 data

Original filing on SEC EDGAR

Bolt Biotherapeutics acquisition adds Prana, but dilution reshapes control | BOLT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.